Fact based stock research
Mezzion Pharma (KOSDAQ:A140410)
KR7140410002
Mezzion Pharma stock research in summary
Mezzion Pharma shares are more expensive than other comparable stocks. While they show above average growth, they are riskily financed, and are poor value. We recommend evaluating whether the future of the company Mezzion Pharma is really as positive as the high price of the shares suggests. If you come to the conclusion that the future for this company is only average, that could be a reason to sell this share.
Latest Obermatt Ranks
Value Rank | 1 | ![]() |
Growth Rank | 92 | ![]() |
Safety Rank | 7 | ![]() |
Combined Rank | 15 | ![]() |
Country | South Korea |
Industry | Pharmaceuticals |
Index | |
Size class | X-Small |
March 26, 2021. Stock data may be delayed. Login to get the most recent research.
Google: Mezzion Pharma
Research History: Mezzion Pharma
RESEARCH HISTORY | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
VALUE | ||||||||
VALUE | n/a |
![]() |
n/a |
![]() |
1 |
![]() |
1 |
![]() |
GROWTH | ||||||||
GROWTH | n/a |
![]() |
n/a |
![]() |
64 |
![]() |
92 |
![]() |
SAFETY | ||||||||
SAFETY | n/a |
![]() |
n/a |
![]() |
6 |
![]() |
7 |
![]() |
COMBINED | ||||||||
COMBINED | n/a |
![]() |
n/a |
![]() |
7 |
![]() |
15 |
![]() |
Value Metrics in Detail
VALUE METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
PRICE VS. REVENUES (P/S) | ||||||||
PRICE VS. REVENUES (P/S) | n/a |
![]() |
n/a |
![]() |
4 |
![]() |
2 |
![]() |
PRICE VS. PROFITS (P/E) | ||||||||
PRICE VS. PROFITS (P/E) | n/a |
![]() |
n/a |
![]() |
1 |
![]() |
1 |
![]() |
PRICE VS. CAPITAL (Market-to-Book) | ||||||||
PRICE VS. CAPITAL (Market-to-Book) | n/a |
![]() |
n/a |
![]() |
1 |
![]() |
1 |
![]() |
DIVIDEND YIELD | ||||||||
DIVIDEND YIELD | n/a |
![]() |
n/a |
![]() |
1 |
![]() |
1 |
![]() |
CONSOLIDATED RANK: VALUE | ||||||||
CONSOLIDATED RANK: VALUE | n/a |
![]() |
n/a |
![]() |
1 |
![]() |
1 |
![]() |
Growth Metrics in Detail
GROWTH METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
REVENUE GROWTH | ||||||||
REVENUE GROWTH | n/a |
![]() |
n/a |
![]() |
67 |
![]() |
92 |
![]() |
PROFIT GROWTH | ||||||||
PROFIT GROWTH | n/a |
![]() |
n/a |
![]() |
7 |
![]() |
21 |
![]() |
STOCK RETURNS | ||||||||
STOCK RETURNS | n/a |
![]() |
n/a |
![]() |
100 |
![]() |
86 |
![]() |
CONSOLIDATED RANK: GROWTH | ||||||||
CONSOLIDATED RANK: GROWTH | n/a |
![]() |
n/a |
![]() |
64 |
![]() |
92 |
![]() |
Safety Metrics in Detail
SAFETY METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
LEVERAGE | ||||||||
LEVERAGE | n/a |
![]() |
n/a |
![]() |
51 |
![]() |
54 |
![]() |
REFINANCING | ||||||||
REFINANCING | n/a |
![]() |
n/a |
![]() |
18 |
![]() |
16 |
![]() |
LIQUIDITY | ||||||||
LIQUIDITY | n/a |
![]() |
n/a |
![]() |
1 |
![]() |
1 |
![]() |
CONSOLIDATED RANK: SAFETY | ||||||||
CONSOLIDATED RANK: SAFETY | n/a |
![]() |
n/a |
![]() |
6 |
![]() |
7 |
![]() |
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Mezzion Pharma from March 26, 2021.
We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.